Antigen-specific autoreactive T cell (None)

Antigen-specific autoreactive T cells are a specialized subset of T lymphocytes that have bypassed central and peripheral tolerance mechanisms to recognize and attack self-antigens, driving the progression of autoimmune diseases (Nature Reviews Immunology, 2015, 15(5):308-322). These cells are characterized by their expression of unique T-cell receptors (TCRs) that bind to specific autoantigenic peptides presented by Major Histocompatibility Complex (MHC) molecules. In conditions like Type 1 diabetes, these cells target pancreatic beta-cell proteins such as insulin or GAD65, while in multiple sclerosis, they target myelin components (NEJM, 2019, 381(7):603-613). Unlike broad immunosuppressants that dampen the entire immune system, modern therapeutic approaches aim to selectively neutralize or reprogram only these pathogenic cells to restore long-term self-tolerance. Strategies include the use of antigen-specific nanoparticles (Navacims), tolerogenic vaccines, and engineered Chimeric Autoantibody Receptor (CAAR) T cells (Science, 2016, 353(6295):179-184). By specifically targeting the autoreactive population, these therapies seek to provide durable clinical remission while preserving the patient's ability to fight infections and cancer. This precision approach represents a significant shift in the treatment of autoimmune disorders, moving away from chronic symptom management toward potential cures.

Other names

Self-reactive T cellsPathogenic T cellsAutoantigen-specific T cellsAutoreactive T lymphocytesAutoreactive T cells

Therapeutic strategies targeting antigen-specific autoreactive T cells primarily focus on inducing immune tolerance through several distinct mechanisms. These include clonal deletion (selective elimination of the pathogenic cells), induction of anergy (rendering the cells non-responsive to self-antigens), and immune redirection (converting inflammatory T cells into regulatory T cells). Specificity is achieved by using MHC-peptide complexes, tolerogenic dendritic cells, or engineered CAAR-T cells that recognize the unique T-cell receptors or surface markers associated with the autoimmune response (Nature Reviews Immunology, 2015; Science, 2016).